This nested project of the Swiss Multiple Sclerosis Cohort (SMSC) is to assess the severity of COVID-19 and the magnitude of antibody response after infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients already treated or not with various immunotherapies for multiple sclerosis followed in the framework of the SMSC.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of severe COVID-19 as defined by the WHO clinical progression scale (Score 6-9)
Timeframe: through study completion, an average of 3 years
COVID-19 related death defined by the WHO clinical progression scale (Score 10)
Timeframe: through study completion, an average of 3 years